Positive multi-center COPD trial with inhaled Bimosiamose
Inhalation of Bimosiamose for 28 days on top of standard bronchodilators was safe and well tolerated in 77 patients with moderate to severe COPD (GOLD II-III). It led to a broad and significant attenuation of airway inflammation and trend towards lung function improvements.
"Our data with Bimosiamose demonstrate a significant step forward in the anti-inflammatory treatment of COPD", said Prof. Wolfgang Meyer-Sabellek, CMO of Revotar. "We will discuss future clinical development of our first in class inhaled drug with international key opinion leaders in Amsterdam at one of the biggest and renowned respiratory conferences worldwide."
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.